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The Parkinson’s disease protein ␣-synuclein disrupts
cellular Rab homeostasis
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Kim A. Caldwell¶, Guy A. Caldwell¶, Jean-Christophe Rochet§, J. Michael McCaffery储, Charles Barlowe**,
and Susan Lindquist*††
*Whitehead Institute for Biomedical Research and Howard Hughes Medical Institute, Cambridge, MA 02142; §Department of Medicinal Chemistry and
Molecular Pharmacology, Purdue University, West Lafayette, IN 47907; ¶Department of Biological Sciences, University of Alabama, Tuscaloosa, AL 35487;
储Integrated Imaging Center and Department of Biology, Johns Hopkins University, Baltimore, MD 21218; **Department of Biochemistry, Dartmouth Medical
School, Hanover, NH 03755; and Departments of †Cell and Developmental Biology and ‡Biochemistry and Biophysics, University of Pennsylvania School of
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␣-Synuclein (␣-syn), a protein of unknown function, is the most
abundant protein in Lewy bodies, the histological hallmark of
Parkinson’s disease (PD). In yeast ␣-syn inhibits endoplasmic reticulum (ER)-to-Golgi (ER3 Golgi) vesicle trafficking, which is rescued
by overexpression of a Rab GTPase that regulates ER3 Golgi
trafficking. The homologous Rab1 rescues ␣-syn toxicity in dopaminergic neuronal models of PD. Here we investigate this conserved feature of ␣-syn pathobiology. In a cell-free system with
purified transport factors ␣-syn inhibited ER3 Golgi trafficking in
an ␣-syn dose-dependent manner. Vesicles budded efficiently from
the ER, but their docking or fusion to Golgi membranes was
inhibited. Thus, the in vivo trafficking problem is due to a direct
effect of ␣-syn on the transport machinery. By ultrastructural
analysis the earliest in vivo defect was an accumulation of morphologically undocked vesicles, starting near the plasma membrane and growing into massive intracellular vesicular clusters in a
dose-dependent manner. By immunofluorescence/immunoelectron microscopy, these clusters were associated both with ␣-syn
and with diverse vesicle markers, suggesting that ␣-syn can impair
multiple trafficking steps. Other Rabs did not ameliorate ␣-syn
toxicity in yeast, but RAB3A, which is highly expressed in neurons
and localized to presynaptic termini, and RAB8A, which is localized
to post-Golgi vesicles, suppressed toxicity in neuronal models of
PD. Thus, ␣-syn causes general defects in vesicle trafficking, to
which dopaminergic neurons are especially sensitive.
endoplasmic reticulum 兩 Rab GTPase 兩 yeasts 兩 vesicle trafficking 兩 Golgi

he protein ␣-Synuclein (␣-syn) is a small presynaptic protein
of undefined function implicated in several neurodegenerative disorders, including Parkinson’s disease (PD), known collectively as the synucleinopathies (1). Mutations in ␣-syn or
overexpression of the WT gene result in early-onset PD in rare
familial forms of the disease. But ␣-syn is also implicated in the
more common sporadic forms. ␣-Syn has the propensity to
aggregate and is found in Lewy bodies, cardinal pathological
features of PD (2).
␣-Syn was initially identified as a synaptic vesicle-associated
protein, although it has also been localized to the cytosol and
nucleus (3, 4). ␣-Syn peripherally associates with synaptic vesicles both in vitro and in vivo (5, 6). Indeed, association with
phospholipid-containing vesicle membranes induces natively
unfolded ␣-syn to adopt an amphipathic ␣-helical secondary
structure (7, 8). In certain contexts, membrane association by
␣-syn is critical for mediating both its toxic and normal functions
(9–11).
Several lines of evidence suggest some role for ␣-syn trafficking at the synapse. ␣-Syn knockout mice are grossly normal but
exhibit reduced synaptic vesicle reserve pools (12) and enhanced
activity-dependent dopamine release (13), both effects likely
attributable to precocious vesicle fusion and exocytosis. Conversely, neuronal cells overexpressing ␣-syn exhibit decreased
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evoked neurotransmitter release owing to an increase in the pool
of docked, but not yet fused, secretory vesicles (14, 15). Other
studies with transgenic and knockout mice suggest that ␣-syn
might function as a chaperone for the assembly of SNARE
protein complexes that are necessary for vesicle fusion with the
plasma membrane (9).
A genetic screen in Saccharomyces cerevisiae resulted in the
identification of endoplasmic reticulum (ER)3Golgi trafficking
genes as potent modifiers of ␣-syn-induced cellular toxicity (16).
Moreover, ␣-syn caused two different cargoes that undergo
different posttranslational modifications en route from the ER
to the Golgi to the vacuole, to stall in a pre-Golgi compartment
(16). ␣-Syn expression also resulted in the accumulation of lipid
droplets and the production of reactive oxygen species (10), but
these occurred after the block in trafficking (ref. 16 and our
unpublished data). Thus, transport defects make an important
early contribution to pathology.
Here we used in vitro transport assays, electron microscopy
(EM), and in vivo imaging to investigate the nature of ␣-syninduced trafficking defects. In vitro ␣-Syn specifically inhibited
vesicle docking and/or fusion, and this resulted in the accumulation of transport vesicles in vivo. ␣-Syn strongly colocalized
with these vesicles, which were variable in size and staining
properties. Indeed, in addition to Ypt1, the Rab that functions
in ER3Golgi transport, several other Rabs colocalized with
␣-syn clusters. Only the ER3Golgi Rab Ypt1 rescued toxicity in
yeast, but we reasoned that the distinct biology of dopaminergic
neurons might make them more sensitive to perturbations in
other trafficking steps. RAB8A is the Rab most closely related
to Rab1 by sequence homology, but it functions in post-Golgi
trafficking. RAB3A is specific to neurons (17), where it concentrates at presynaptic sites and plays a role in tethering and
docking neurotransmitter vesicles in preparation for fusion and
release. Both of these Rabs rescued ␣-syn-induced degeneration
in our neuronal models of PD. Our findings provide a molecular
explanation for a connection between the normal and pathogenic functions of ␣-syn. They also indicate that the highly
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Fig. 1. ␣-Syn accumulation inhibits in vitro ER3 Golgi vesicular transport. (A)
Reconstituted transport reactions in washed semiintact yeast cells containing
[35S]glyco-pro-␣-factor were incubated with increasing amounts of purified
␣-syn or the ␣-syn A53T variant. After 60 min at 25°C, the amount of Golgimodified [35S]glyco-pro-␣-factor was measured to determine transport efficiency. Transport in the absence of reconstitution factors was 2.4%, and plots
represent levels minus this background. (B) In vitro reactions as in A comparing
the influence of ␣-syn and the A30P variant on reconstituted transport when
added at 20 M and 40 M. (C) Semiintact cells as in A were incubated with
COPII proteins or COPII plus Uso1 to measure budding and tethering in the
presence or absence of ␣-syn (40 M). After 25 min at 25°C, freely diffusible
vesicles containing [35S]glyco-pro-␣-factor were separated from semiintact
cells by centrifugation, and percentages of budded vesicles were determined.

specific pathologies found in the synucleinopathies are not due
to biological processes that are restricted to the affected cells.
Rather, they are due to the particular vulnerability of neurons
(with their generally more extreme trafficking requirements)
and dopaminergic neurons (with their relatively problematic
neurotransmitter) to a general cellular defect.
Results
␣-Syn Inhibits a Specific Step in Transport. ER3Golgi trafficking
involves a series of steps, consisting of COPII-dependent vesicle
budding from the ER, tethering and docking to target membranes, and finally SNARE protein-dependent vesicle fusion
(18). We first asked whether ␣-syn would inhibit ER3Golgi
transport in a reconstituted cell-free assay (19). This assay
measures the amount of ER-localized [35S]glyco-pro-␣-factor
that is transported to the Golgi by detecting a Golgi-specific
carbohydrate modification (␣-1,6-mannose). WT yeast cells not
expressing ␣-syn were permeabilized and washed to deplete
them of soluble proteins. ER membranes in these ‘‘semiintact’’
cells were then loaded with [35S]glyco-pro-␣-factor and incubated with or without the purified coat proteins and fusion
factors that reconstitute in vitro transport (19). The factors
resulted in an ⬇10-fold increase (from 2.4% to 27.7%) in
ER3Golgi transport. Addition of purified soluble ␣-syn inhibited this transport in a dose-dependent manner (Fig. 1A). WT
␣-syn and a point mutation (A53) that causes early-onset PD in
humans and is more toxic than WT ␣-syn in yeast had the same
effect. The increased toxicity of A53T may be downstream of the
trafficking defect, perhaps related to its greater tendency to
aggregate (20). Importantly, another ␣-syn point mutant (A30P),
which does not bind membranes and is not toxic in yeast (10, 21),
did not inhibit transport (Fig. 1B), nor did an unrelated control
protein, soybean trypsin inhibitor (data not shown). Thus, the
strong effects of ␣-syn on ER3Golgi trafficking observed in vivo
(16) are likely attributable to its specific interactions with the
trafficking machinery rather than to indirect effects on signaling
cascades or other perturbations.
Next we tested subreactions in ER3Golgi transport. We
incubated washed semiintact cells containing [35S]glyco-pro-␣factor with COPII proteins and an ATP/GTP regeneration
system. During the course of the incubation, freely diffusible
ER-derived COPII vesicles were released from the ER. Adding
a concentration of ␣-syn (40 M) that was sufficient to block
transport by 50% actually increased the amount of freely diffusible vesicles (from 45% to 65%) (Fig. 1C). Thus, ␣-syn does
146 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0710685105

not inhibit the budding of vesicles from the ER. The increase in
free vesicles seemed likely to reflect inhibition in downstream
events. Tethering factors facilitate the docking of vesicles onto
target membranes. In the absence of ␣-syn, adding the tethering
factor Uso1 (the yeast homolog of p115 in humans) to vesicle
budding reactions reduced the amount of freely diffusible vesicles (from 45% to 29%) because they were now tethered to and
pelleted with Golgi acceptor membranes (Fig. 1B). Uso1 also
reduced the amount of diffusible vesicles (from 65% to 38%) in
the presence of ␣-syn, but there were still more diffusible vesicles
than with Uso1 alone (29%) (Fig. 1C). Together, these data
suggest that ␣-syn inhibits a late stage of ER3Golgi vesicular
transport, perhaps reducing the ability of the Uso1 tethering
complex to coordinate the events that lead to membrane fusion.
Similar effects have been observed in mammalian transport
assays (W. Balch, personal communication).
Vesicles accumulate in vivo in a time- and dosage-dependent
manner. To evaluate the consequences of ␣-syn overexpression
at an ultrastructural level, we performed thin-section EM. Yeast
cells expressing one copy of ␣-syn (1⫻, which causes no overt
reduction in growth) were compared with two other strains.
Each carried two copies of ␣-syn (2⫻), but these were integrated
at different chromosomal locations. These expressed ␣-syn at
different levels with correspondingly different toxicities. As
measured by f luorescence-activated cell sorting (data not
shown), the intermediate-toxicity strain (IntTox) expressed
⬇30–40% less ␣-syn than the higher-toxicity strain (HiTox) (10,
16). In all of the strains the ␣-syn genes were under the control
of a galactose-regulated promoter, GAL1, to prevent expression
in normal media.
After transfer to galactose, cells carrying one copy of ␣-syn
accumulated a small number of vesicles relative to cells carrying
the vector alone. Strikingly, it was common to see these vesicles
associated with the peripheral ER, consistent with ␣-syn being
a negative regulator of vesicle fusion events (15) (Fig. 2 A–C).
Such vesicles were rarely if ever seen cells expressing the vector
alone. After 3 h of galactose induction in the two-copy HiTox
strain, small vesicle clusters accumulated primarily at the cellular
periphery, proximal to the peripheral ER and plasma membrane
(Fig. 2D). At 5 h these clusters had grown massive and intruded
into the cell interior, taking on a more juxta-vacuolar/nuclear
localization (Fig. 2E). Similar vesicles were observed in the
two-copy IntTox strain, but they accumulated more slowly and
were less abundant at equivalent time points [supporting information (SI) Fig. 5]. Thus, as for trafficking defect in the cell-free
assays, the ultrastructural defect in vesicle accumulation was
dosage-dependent.
Some of the accumulated vesicles were similar in size (50–70 nm)
and appearance to vesicles seen in certain sec mutants blocked at
the ER3Golgi transport step (22). But many were larger, particularly in the HiTox strain (80–100 nm, some even larger), suggestive
of Golgi vesiculation or some fusion of clustered vesicles. Vesicle
staining densities were also heterogeneous in these cells.
Fluorescence Microscopy to Visualize ␣-Syn Dynamics. Fluorescence

analysis of ␣-syn-GFP accumulation revealed an initial concentration at the plasma membrane, followed by the formation of
many small ␣-syn foci near the cell periphery. As with vesicles
detected by EM, these grew in size over time and eventually
coalesced into a few large intracellular clusters (Fig. 2H).
Moreover, these foci accumulated more rapidly and grew to
larger sizes in HiTox than in IntTox cells (SI Fig. 5 D–G).
Expressing Ypt1 from the strong GAL1 promoter rescued the
growth defect in IntTox cells (16) and strongly reduced ␣-syn foci
(Fig. 2I). Expressing Ypt1 from the weaker GPD promoter did
not rescue toxicity or eliminate ␣-syn foci. Even the high levels
of GAL1-expressed Ypt1 did not eliminate foci or toxicity in
HiTox cells (data not shown). Thus, the formation of ␣-syn foci
Gitler et al.

Fig. 2. EM and fluorescence microscopy of ␣-syn overexpression reveals a
time- and dosage-dependent accumulation of transport vesicles. (A and B)
Control strain (A) and one-copy (1⫻) ␣-syn strain (B) at 3 h. (C) Higher
magnification of vesicles accumulated near peripheral ER at 3 h in the onecopy strain. (D and E) Time course of ␣-syn expression [HiTox two-copy (2⫻)
strain] beginning at 3 h (D) and proceeding through 5 h (E). (F and G) Indirect
immunolabeling of ultrathin cryosections at 5 h after induction demonstrates
localization of ␣-syn-GFP with accumulated vesicle cluster (F; 10 nm Au,
␣-syn-GFP) and colocalization with ␣-1,6-mannose (G; 6 nm Au, ␣-syn-GFP; 12
nm Au, ␣-1,6-mannose). m, mitochondria; n, nucleus; pm, plasma membrane;
G, Golgi. Asterisks indicate vesicle clusters in D and E. (H) Visualization of ␣-syn
dynamics over time. At early time points (2 h) ␣-syn-GFP (IntTox 2⫻ strain)
localized to the plasma membrane. By 3.5 h many small ␣-syn-GFP-positive
inclusions formed adjacent to the plasma membrane and over time (5 h) began
to coalesce into a few large inclusions localized close to the plasma membrane
as well as in the interior of the cell (6 h). (I) Ypt1 overexpression eliminates
␣-syn-YFP inclusions. At 6 h, ␣-syn-YFP-expressing cells contain many vesicular
inclusions when transformed with an empty vector. These are eliminated in
cells transformed with a Ypt1 expression plasmid. (Scale bars: 0.5 m.)

depended on both the dosage of ␣-syn and suppressor and in all
cases strongly correlated with toxicity.
Colocalization of ␣-Syn and Vesicle Clusters. ␣-Syn interacts with

membranes and also has a tendency to misfold and aggregate.
The clusters of diverse vesicles might be due to ␣-syn-coated
vesicles providing a multivalent scaffold to trap additional
vesicles. If the vesicle defect is a direct result of ␣-syn’s interGitler et al.

␣-Syn Perturbs Multiple Trafficking Steps. We previously reported
that ␣-syn causes a defect in ER3Golgi trafficking. The diverse
size and staining properties of the vesicles detected by EM
relative to those expected from a simple ER3Golgi block (23)
prompted us to ask whether later stages might also be affected.
Indeed, using double-label immunoEM we detected many vesicle
clusters containing ␣-1,6-mannose residues, a Golgi-specific
modification (Fig. 2 F and G; 6 nm Au, ␣-syn; 12 nm Au,
␣-1,6-mannose).
ImmunoEM is limited by the availability of high-affinity
antibodies against epitopes that are well preserved after fixation.
To examine other vesicles we created a panel of centromeric
(low-copy) plasmids to express a wide variety of Rabs fused to
the cyan fluorescent protein variant Cerulean (24). This enabled
the visualization of ␣-syn-YFP relative to each Rab protein.
Similar N-terminal Rab fusions have been shown to be fully
functional (25). We took advantage of the fact that GPD-driven
expression of Ypt1 does not rescue ␣-syn localization in IntTox
cells to examine its localization in comparison with that of other
Rabs under the control of the same promoter.
Based on previous reports, except for a slightly increased
background staining each Cerulean-Rab fusion protein was
localized properly in WT cells (ref. 25 and data not shown) and
in cells expressing one copy of ␣-syn (Fig. 3 B, F, J, N, R, V, and
Z). However, in cells expressing two copies of ␣-syn, Rab
localization was profoundly altered. Each of the Rabs tested:
Ypt1 (ER3Golgi), Ypt31 (late/post-Golgi), Sec4 (secretory
vesicles to plasma membrane), Ypt6 (endosome to Golgi), Vps21
and Ypt52 (early endosome to late endosome), and Ypt7 (late
endosome to vacuole) colocalized with the ␣-syn foci (Fig. 3 D,
H, L, P, T, X, and BB). This colocalization was detectable as soon
as strong ␣-syn foci accumulated.
As a specificity control, we examined localization of the
clathrin coat protein Chc1. Clathrin promotes the budding of
vesicles from the plasma membrane during endocytosis, but the
clathrin cages that engulf these vesicles disassemble immediately
after vesicle scission. In striking contrast with the many Rabs we
examined, Chc1 localization was not altered in the cells expressing two copies of ␣-syn, and it did not colocalize with ␣-syn (Fig.
3 CC–FF).
We also looked for colocalization of ␣-syn with two Golgi
proteins: Gos1, a v-SNARE protein that localizes to intra-Golgi
vesicles, and Sec7, a GTP exchange factor for Arf that localizes
mainly to the late Golgi but not particularly to vesicles. After
induction of ␣-syn, the normally small, Golgi-like puncta formed
by Cerulean-Gos1 enlarged and colocalized with the large ␣-syn
foci (Fig. 3 GG–JJ). In contrast, Sec7-Cerulean maintained a
Golgi-like punctate pattern clearly distinct from the ␣-syn foci
(Fig. 3 KK–NN). ␣-Syn also did not colocalize with Kar1, an ER
marker (data not shown). Thus, although ␣-syn causes a global
PNAS 兩 January 8, 2008 兩 vol. 105 兩 no. 1 兩 147

CELL BIOLOGY

action with the trafficking machinery, it should concentrate over
accumulating vesicles. To test this, cells expressing an ␣-syn-GFP
fusion were processed for indirect immunoelectron microscopy
(immunoEM) with ultrathin cryosections and an antibody
directed against GFP.
␣-Syn-GFP fusions can behave aberrantly in mammalian cells,
but these problems do not occur in yeast. The fusion protein was
not cleaved (data not shown), and its biology was identical to
untagged ␣-syn (10). ImmunoEM requires a compromise between mild fixation, needed to preserve antigenic epitopes, and
strong fixation, needed to visualize ultrastructure. GFP’s resistance to denaturation allowed us to maintain immunoreactivity
under conditions where vesicle clusters were still identifiable.
␣-Syn colocalized with the vesicle clusters very strongly. Thus, as
in the cell-free assays, the localization of ␣-syn to membranes at
high concentrations allows vesicles to bud but blocks their
docking and/or fusion (Fig. 2F).

Ypt1, but not other Rab proteins, suppress ␣-syn toxicity when
overexpressed (16). We overexpressed each of the above Rab
proteins from a GAL1 promoter in IntTox cells. Consistent with
our previous report, only Ypt1, and to a very slight degree Ypt6,
suppressed toxicity (ref. 16 and data not shown). Apparently
Ypt1 is the most critical Rab for suppressing ␣-syn toxicity in
yeast.

Fig. 3. ␣-Syn perturbs Rab GTPase homeostasis. Fluorescence microscopy of
1⫻ or 2⫻ ␣-syn-YFP-expressing cells in the presence of CFP-tagged Rab proteins. In 1⫻ ␣-syn cells (A, E, I, M, Q, U, Y, CC, GG, and KK), each CFP-Rab fusion
localized properly based on published reports (B, F, J, N, R, V, and Z). In 2⫻
␣-syn cells (C, G, K, O, S, W, and AA), each Rab was sequestered into the ␣-syn
inclusions (D, H, L, P, T, X, and BB). The localization of a CFP fusion to the
clathrin heavy chain protein Chc1 (DD) was not altered in 2⫻ ␣-syn cells (EE and
FF), indicating that the presence of a CFP tag was not responsible for the
relocalization of the Rab proteins. The Golgi vesicle-localized v-SNARE Gos1
(HH) colocalized with ␣-syn inclusions (II and JJ), but Sec7p (KK and LL), an ARF
GTP exchange factor, did not (MM and NN).

defect in trafficking in its pathogenic state it remains highly
specific to trafficking vesicles.
These results prompted us to reevaluate previous findings that
148 兩 www.pnas.org兾cgi兾doi兾10.1073兾pnas.0710685105

RAB3A and RAB8A Protect Against ␣-Syn-Induced Neuron Loss. The
elongated, highly ramified architecture of neuronal cells and the
special demands of regulated dopamine release prompted us to
ask whether other Rabs might be more important in combating
␣-syn toxicity in dopaminergic (DA) neurons than they are in
yeast. RAB8A, the human homolog of yeast Sec4, is the closest
paralog to human RAB1A (55% identical, 75% similar).
RAB8A, like yeast Sec4, is localized on post-Golgi vesicles where
it facilitates targeting to areas of polarized membrane growth.
Given the neuronal specificity of RAB3A expression and the
presynaptic terminal localization of ␣-syn, RAB3A was also an
attractive candidate to test.
To evaluate the ability of these Rabs to modify ␣-syn-induced
toxicity in DA neurons we used two very different models. The
nematode Caenorhabditis elegans offers the advantage of testing
DA neurons wired in their natural context to other neurons in
a whole animal. Rat primary midbrain cultures lack this advantage but are evolutionarily much closer to human neurons and
offer the additional advantage of detecting differential sensitivity of DA neurons (a hallmark of PD) and selective rescue of
those neurons that are most affected by ␣-syn pathology (a
therapeutic goal).
In the C. elegans PD model a promoter specific to DA neurons
(Pdat-1) drives expression of WT human ␣-syn. Because nematode development is so invariable, any deviation from the normal
number of DA neurons is highly significant and is readily scored.
Six anterior DA neurons are readily visualized in worms carrying
a Pdat-1::gfp construct. For technical ease (16) we previously
scored only four. Here we scored all six to provide a more
rigorous assay. During the course of aging, overexpression of
human ␣-syn reduced the number of worms with the WT number
of neurons to ⬇15%. Mouse Rab1 (the clone most readily
available and encoding a protein of identical sequence to the
human protein) increased it to ⬇20%. Human RAB3A increased rescue to 25%, and human RAB8A increased rescue to
40% (Fig. 4A). This is the strongest rescue yet achieved with any
of the many constructs that have been tested in this nematode
model (ref. 16 and our unpublished observations).
The rat primary cell model employs mixed neuronal cultures
derived from embryonic rats at day 17. All cell types in the
culture were indiscriminately infected with lentivirus encoding a
mutant form of ␣-syn linked to early-onset PD (A53T). DA
neurons, scored by tyrosine hydroxylase staining, were more
susceptible to the toxicity of this protein relative to total neurons,
scored by MAP2 staining (16). Control viruses expressing ␤-galactosidase had no protective effect (data not shown). In contrast, viruses encoding Rab1, RAB3A, or RAB8A provided
strong protection (Fig. 4B).

Discussion
Using in vitro assays with purified transport components and a
combination of in vivo assays, we demonstrate that, as ␣-syn
accumulates to toxic levels, transport vesicles bud normally and are
targeted to the cell periphery. However, the transition of these
vesicles to docking and/or fusion is greatly impaired. Unlike the
vesicles accumulating in sec mutants blocked at specific trafficking
steps, the profusion of vesicles accumulating when ␣-syn was
expressed at toxic levels were heterogeneous in size and staining
properties. Furthermore, they were highly clustered, initially forming near the peripheral ER and plasma membrane but later
Gitler et al.

coalescing into intracellular masses. By immunoEM, these vesicles
colocalized with ␣-syn, confirming results of cell-free assays indicating that ␣-syn effects transport via direct interaction with the
trafficking machinery. We speculate that it is three properties of
␣-syn—its affinity for acidic phospholipid-rich membranes (6), its
inhibition of vesicle docking or fusion, and its tendency to misfold
and oligomerize (11)—that cause vesicle clustering and contribute
to the pathobiology of ␣-syn.
Although only the ER3Golgi Ypt1 significantly affected
␣-syn toxicity (ref. 16 and data herein), by EM and fluorescence
immunomicroscopy vesicles from different parts of the exocytic
and endocytic pathways are sequestered in ␣-syn clusters. Because several of their associated Rabs are not essential in yeast
they might not have been picked up in our genetic screen because
perturbations in their function were simply not pivotal to survival. This seems unlikely. Sec4p, like Ypt1, is essential and
functions at the last steps of exocytosis, steps analogous to
synaptic vesicle docking and fusion in neurons. It might be that
Sec4p overexpression does not rescue in yeast simply because its
dysfunction in our cells is of secondary importance to that of
Ypt1 or because the particular level of expression achieved with
our construct was insufficient.
Critically, in higher organisms two other Rab proteins, one
chosen because it is a close paralog to Rab1 (RAB8A, the
mammalian homolog of Sec4p), the other because it is neuronspecific and functions at the synapse (RAB3A), were able to
provide substantial rescue against ␣-syn-induced degeneration
of DA neurons. The fact that rescue was achieved in two very
different neuronal models—in the intact nervous system of the
nematode and in dispersed primary rat neuronal cultures, which
allow assessment of the differential sensitivity and rescue of DA
neurons—argues that ␣-syn broadly perturbs vesicle trafficking
and that these perturbations are relevant to its pathobiology. The
secretory pathway is highly conserved between yeast and mammals; however, there is higher complexity in the mammalian
membrane transport apparatus, as evidenced by the much
greater number of Rabs. Evidence for ␣-syn-mediated disrupGitler et al.

Materials and Methods
Yeast Strains and Constructs. Strains were constructed as detailed in SI Materials and Methods. In the HiTox strain, two copies of ␣-syn were integrated
into the URA3 and TRP1 loci; for the IntTox strain, the ␣-syn cassettes were
integrated at HIS3 and TRP1. For the fluorescence microscopy experiments,
fusion constructs were generated by using the pRS series-based Gateway
vectors (24). The secretory pathway proteins were cloned into pAG416GPDCerulean-ccdB to generate N-terminal fusions to Cerulean, expressed from the
GPD promoter. We fused Cerulean to the C terminus of Sec7 using
pAG416GPD-ccdB-Cerulean.
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Fig. 4. Rab1, RAB3A, and RAB8A protect against ␣-syn-induced dopaminergic neuron loss. (A) Multiple Rab GTPases ameliorate ␣-syn-induced neurodegeneration in C. elegans. DA neurons of 7-day-old transgenic nematodes
overexpressing ␣-syn along with Rab1, RAB3A, or RAB8A were analyzed. Each
Rab tested significantly suppressed ␣-syn toxicity in worm DA neurons (*, P ⬍
0.05, Student’s t test). For each gene tested, three transgenic lines were
analyzed; a worm was scored as WT when all six anterior DA neurons (four CEP
and two ADE neurons) were intact. (B) Primary rat midbrain cultures were
transduced with A53T lentivirus (multiplicity of infection ⫽ 5) in the absence
or presence of lentivirus encoding RAB3A, RAB8A, or Rab1 (multiplicity of
infection of each Rab virus ⫽ 2). Control cells were incubated in the absence
of lentivirus. Dopaminergic cell viability was determined by staining with
antibodies specific for MAP2 and TH and is expressed as the percentage of
MAP2-positive neurons that were also TH-positive (two to three independent
experiments; at least 100 cells counted per experiment for each treatment).
The data are plotted as the mean ⫾ SEM. **, P ⬍ 0.001 vs. A53T virus alone,
one-way ANOVA with Newman–Keuls posttest.

tion of ER3Golgi trafficking has been reported in mammalian
cells (ref. 26 and W. Balch, personal communication). And
Rab1, which controls this trafficking step, rescues in all three of
the systems we employ here. It might be, therefore, that the
trafficking defect starts at the ER3Golgi step and that the
trapping of other vesicles is secondary to that. Alternatively,
␣-syn might most strongly affect the very closely related Rab1
and RAB8A, secondarily involving others. Or multiple Rabs
might be affected at the same time. In any case, these observations suggest that at least some forms of PD, which would at first
sight have appeared to be due to biology highly specific to certain
neurons, might actually be caused by defects in very basic aspects
of cell biology that particular neurons are simply more sensitive
to. Indeed, vesicle accumulations, strikingly similar to what we
see in yeast cells, have been observed in neurons before Lewy
body formation (27). Furthermore, vesicle accumulations are
often found in proximity to Lewy bodies in later stages of disease
(28, 29).
Neurons have extremely elongated and highly ramified cellular architectures. Any general trafficking problems would be
expected to affect them more strongly than most cells. Furthermore, DA neurons transport a particularly dangerous neurotransmitter. Dopamine is made in the cytoplasm and is highly
prone to producing reactive oxygen species until sequestered
into vesicles (30–32). A defect in the production of vesicles would
lead to a defect in dopamine sequestration, potentially causing
some of the oxidative damage that is characteristic of PD. If a
defect also exists in later stages of vesicle trafficking, this would
catch DA neurons in a triple-sided vise. In addition to increased
cytosolic dopamine, there would be fewer dopamine-containing
vesicles to release in response to appropriate signals, and the
release of those vesicles that are available would be compromised. Why some dopamine neurons are spared and why certain
other neurons are susceptible (e.g., pyramidal neuronal loss in
the presupplementary motor area) might relate to aspects of
biology not captured by ␣-syn toxicity alone or to other metabolic features (e.g., relative rates of respiration, iron accumulation) that play into ␣-syn toxicity in a yet undefined way. Indeed,
genome-wide genetic analysis in yeast (A.D.G., A. D. Cashikar,
K.E.S., S.H., E. Yeger-Lotem, M. Geddie, K. J. Hill, E. Fraenkel,
K.A.C., G.A.C., A. A. Cooper, J.-C.R., and S.L., unpublished
data) and the effects of chemical compounds on ␣-syn toxicity
in yeast and neurons (L.J.S., T. F. Outeiro, E. Yeger-Lotem, P.
K. Auluck, K.E.S., S. Cao, S.H., K. Hill, K.A.C., G. Bell, A. A.
Cooper, G.A.C., J.M.M., J.-C.R., and S.L., unpublished data)
point to many other features of cell biology that impinge on ␣-syn
toxicity.
A proposed role for ␣-syn under normal physiological conditions, as a negative regulator of synaptic vesicle priming before
fusion (14), is completely consistent with our results. Such a
function might be hyperactivated during pathogenesis because of
inappropriate ␣-syn expression or defective ␣-syn degradation,
both with the potential to exacerbate problems with ␣-syn
oligomerization and vesicle trapping. Thus, the normal and toxic
functions of ␣-syn might be more closely related than previously
realized (15).

In Vitro Transport Assays. ␣-Syn proteins were purified as described in SI
Materials and Methods, and protein concentration was determined by Bradford assay in relation to BSA standards. Yeast semiintact cells were prepared
from strain CBY740 (MAT␣ his3 leu2 lys2 ura3) as described previously (19). In
vitro assays for vesicle budding, tethering, and fusion have been published
previously (19). Plotted data points are the average of duplicate determinations with error bars indicating the range.

several fields were collected, and the images were deblurred by using a
nearest neighbor algorithm in Axiovision software.
C. elegans and rat primary midbrain neurons were prepared and maintained following standard procedures and analyzed as described previously
(16) with minor modifications detailed in SI Materials and Methods.

Microscopy. Conventional and immunoEM were performed as detailed in SI
Materials and Methods. For fluorescence microscopy experiments, yeast
strains were grown to stationary phase in glucose media. Raffinose media was
inoculated with an aliquot of the culture and grown to early- to mid-log phase
at 30°C. Cultures were spun down, resuspended in galactose-containing media, and incubated for 6 h to induce expression of ␣-syn-YFP before being fixed
in 4% formaldehyde/50 mM KPi (pH 6.5)/1 mM MgCl2 on ice for 1 h, washed
twice in PBS, and resuspended in a small volume of PBS for microscopy studies.
Images were obtained by using a Zeiss Axiovert 200 microscope. Z-stacks of
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